Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 7
Submit an article Journal homepage
139
Views
24
CrossRef citations to date
0
Altmetric
Miscellaneous

VLA-4 antagonists

Jefferson W Tilley Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ 07110, USA, E-mail: [email protected]
Pages 991-1008 | Published online: 25 Feb 2005

Bibliography

  • ERLE DJ, BRISKIN MJ, BUTCHER EC, PARDO A, LAZAROVITS Al, TIDWELL M: Expression and function of the MAdCAM-1 receptor, integrin a487, on human leukocytes. j. Immunol (1994) 153:517–528.
  • HENDERSON RB, LIM LHK, TESSIER PA et al.: The use of lymphocyte function-associated antigen deficient mice to determine the role of LFA-1, Mac-1 and a4 integrin in the inflammatory response of neutrophils. j. Exp. Med. (2001) 194(2):219–226.
  • OSBORN L, VASSALLO C, BROWNING BG et al: Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (a431). j Cell Biol. (1994) 124(4):601–608.
  • •Describes mutagenesis experiments that define the major binding epitope for VLA-4 on VCAM.
  • RENZ ME, CHIU H, JONES S et al: Structural requirements for adhesion of soluble recombinant murine vascular cell adhesion molecule-1 to a481. j Cell Biol (1994) 125:1395–1406.
  • •Describes mutagenesis experiments that define the major binding epitope for VLA-4 on VCAM.
  • CLEMENTS JM, NEWHAM P, SHEPHERD M et al.: Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. j. Cell Sci. 107:2127-2135.
  • •Describes mutagenesis experiments that define the major binding epitope for VLA-4 on VCAM.
  • CHIU HH, CROWE DT, RENZ ME, PRESTA LG, JONES S, WEISSMAN IL, FONG S: Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with a481 and a4I37 under different activity states. j. Immunol (1995) 155:5257–5267.
  • •Describes mutagenesis experiments that define the major binding epitope for VLA-4 on VCAM.
  • JONES EY, HARLOS K, BOTTOMLEY MJ et al.: Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution. Nature (1995) 373:539–544.
  • •Reports the crystal structure of the portion of VCAM responsible for binding VLA-4.
  • WANG JH, PEPINSKY RB, STEHLE T etal.: The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): A cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1 a4 integrin interaction. Proc. Natl. Acad. Sci. USA (1995) 92:5714–5718.
  • •Reports the crystal structure of the portion of VCAM responsible for binding VLA-4.
  • MAKAREM R, NE WHAM P, ASKARI JA etal.: Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin a481. J. Bic/. Chem. (1994) 269:4005–4011.
  • KOMORIYA A, GREEN IJ, MERVI M etal.: The minimal essential sequence for a major cell type-specific adhesion site (CS-1) within the alternatively spliced Type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. j Biol. Chem. (1991) 266:15075–15079.
  • JONGEWAARD IN, AI PM, SMITH JW: The Type III connecting segment of fibronectin contains an aspartic acid residue that regulates the rate of binding to integrin a481. Cell Adhesion Comm. (1996) 3:487–495.
  • BAYLESS KJ, DAVIS GE: Identification of dual a481 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. ?Biol. Chem. (2001) 276:13483–13489.
  • SPRING FA, PARSONS SF, ORTLEPP S etal.: Intercellular adhesion molecule-4 binds a4131 and a+-family integrins through novel integrin-binding mechanisms. Blood (2001) 98(2):458–466.
  • BRISKIN M, WINSON-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. Pathol (1997) 151:97–110.
  • LIU S, THOMAS SM, WOODSIDE DG etal.: Binding of paxillin to a4 integrins modifies integrin-dependent biological responses. Nature (1999) 402:676–681.
  • HAN J, LIU, S, ROSE, DM, SCHLAEPFER DD, MCDONALD H, GINSBERG MH: Phosphorylation of the integrin a4 cytoplasmic domain regulates paxillin binding. I Biol. Chem. (2001) 276:40903–40909.
  • ANDREWS RE KEPLEY CL, YOUSSEF L, WILSON RS, OLIVER JM: Regulation of the very late antigen-4-mediated adhesive activity of normal and nonreleaser basophils: roles for Src, Syk and phosphatidylinositol 3-kinase. j. Leukocyte Biol. (2001) 70(5):776–782.
  • HUGHES PE, PFAFF M: Integrin affinity modulation. Trend Cell Biol. (1998) 8:359–364.
  • BOCHNER BS: Road signs guiding leukocytes along the inflammation superhighway. j. Allergy Clin. Immunol (2000) 106:817–828.
  • SCHWARTZ MA, SCHALLER MD, GINSBERG MH: Integrins: emerging paradigms of signal transduction. Ann. Rev Cell Dev. Biol. (1995) 11:549–599.
  • LU C, TAKAGI J, SPRINGER TA: Association of the membrane proximal regions of the a and 13 subunit cytoplasmic domains constrains an integrin in the inactive state. j. Biol. Chem. (2001) 276:14642–14648.
  • HUMPHRIES MJ: Integrin Structure. Biochem. Soc. Trans. (2000) 28:311–329.
  • SPRINGER TA: Folding of the N-terminal, ligand-binding region of integrin asubunits into a I3-propeller domain. Proc. Natl. Acad. Li. USA (1997) 94:65–72.
  • •Theoretical study predicting the conformation of the a-subunit of %IV
  • TAKAGI J, BEGLOVA N, YALAMANCHILI P, BLACKLOW SC, SPRINGER TA: Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin 13- subunits. Proc. Natl. Acad. Li. USA (2001) 98(20):11175–11180.
  • YOU TJ, MAXWELL DS, KOGAN TP, CHEN Q et al.: A 3D structure model of integrin a481 complex: Construction of a homology model of I31 and ligand binding analysis. Biophysical J. (2002) 82:447–457.
  • XIONG J-P, STEHLE T, DIEFENBACH B: Crystal Structure of the extracellular segment of integrin avi33. Science (2001) 294:339–345.
  • ••Reports the first crystal structure of theextracellular domains of an integrin together with these domains including a bound ligand.
  • XIONG JP, STEHLE T, ZHANG R et al.: Crystal structure of the extracellular segment of integrin ad33 in complex with an Arg-Gly-Asp ligand. Science (2002) 296:151–155.
  • ••Reports the first crystal structure of theextracellular domains of an integrin together with these domains including a bound ligand.
  • LEITINGER B, HOGG N: From crystal clear ligand binding to designer I domains. Nat. Struc. Biol. (2000) 7:614–616.
  • HUMPHRIES MJ: Integrin cell adhesion receptors and the concept of agonism. TIPS (2000) 21:29–32.
  • PACHECO KA, TARKOWSKI M, KLEMM J, ROSENWASSER LJ: CD49d Expression and function on allergen-stimulated T cells from blood and airway. Am. Respir Cell Mal Biol. (1998) 18:286–293.
  • BOCCHINO V, BERTORELLI G, D1PPOLITO R et al: The increased number of very late activation-4 positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients. j Allergy Chit. Immunol (2000) 105:65–70.
  • MACKAY IR, ROSEN FS: T-cell function and migration. N Eng] I Med. (2000) 343:1020–1034.
  • BERLIN C, BARGATZE RE CAMPBELL JJ etal.: a4 Integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell (1995) 80:413–422.
  • JOHNSTON B, ISSEKUTZ TB, KUBES P: The a4-integrin supports leukocyte rolling and adhesion in chronically inflamed postcapillary venules in vivo. j Exp. Med. (1996) 183:1995–2006.
  • WARDLAW AJ: Adhesion receptors. Drugs Future (1999) 24:279–286.
  • GANG L: Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin. Ther. Patents (2001) 11(9):1383–1393.
  • OHKAWARA Y, YAMAUCHI K, MARUYAMA N etal.: In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with airflow limitation: in vivo evidence of VCAM-1/ VLA-4 interaction in selective eosinophil infiltration. Am. j Respir: Cell Mol Biol. (1995) 12:4–12.
  • •Reports the increase in VCAM levels in asthmatic patients.
  • ZANGRILLI JG, SHAVER JR, CIRELLI RA et al: VCAM-1 levels after segmental challenge correlate with eosinophil influx and IL-4 and IL-5 production, and the late phase response. Am. j Respir: Grit. Care Med. (1995) 151:1346–1353.
  • •Reports the increase in VCAM levels in asthmatic patients.
  • BORCHERS MT, CROSBY J, FARMER S et al: Blockade of CD49d inhibits allergic airway pathologies independent of effects on leukocyte recruitment. Am. I Physic] (2001) 280 (4)1813–L821.
  • •Reports on the therpeutic potential of anti-VLA-4 antibodies in animal models of allergic asthma.
  • HENDERSON WR, CHI EY, ALBERT RK etal.: Blockade of CD-49d (a4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. j Cl/n. Invest (1997) 100:3083–3092.
  • •Reports on the therpeutic potential of anti-VLA-4 antibodies in animal models of allergic asthma.
  • RICHARDS IM, KOLBASA KP, HATFIELD CA et al.: Role of very late activation antigen-4 in the lungs and airway lumen of sensitized brown Norway rats. Am. ?Respir: Cell Mol Biol. (1996) 15:172–183.
  • •Reports on the therpeutic potential of anti-VLA-4 antibodies in animal models of allergic asthma.
  • SAGARA H, MATSUDA H, WADA N et al: A monoclonal antibody against very late activation antigen-4 inhibits eosinophil accumulation and late asthmatic response in a guinea pig model of asthma. Int. Arch. Allergy Immunol (1997) 112:287–294.
  • •Reports on the therpeutic potential of anti-VLA-4 antibodies in animal models of allergic asthma.
  • LIN KC, ATEEQ HS, HSIUNG SH et al: Selective tight-binding inhibitors of integrin a4I31 that inhibit allergic airway responses. ?Med. Chem. (1999) 42:920–934.
  • KRAUSE BRIAN R, AUERBACH BRUCE J, BOCAN THOMAS MA: Direct vascular targets for atherosclerosis prevention. Curr. Med. Chem. Immunol Endocr. Metab. Agents (2001) 1:39–46.
  • SAXENA U, MEDFORD RIVI: Vascular adhesion molecule-I (VCAM-1), an inflammatory gene target for new therapeutics. Curr. Opin. Cardiovasc. Pul Rena] Invest. Drugs (2000) 2:258–262.
  • MISIAKOS EP, KOURAKLIS G, AGAPITOS E et al: Expression of PDGF-A, TGEb and VCAM-1 during the developmental stages of experimental atherosclerosis. Eur. Surg. Res. (2001) 33(4):264–269.
  • CYBULSKY MI, IIYAMA K, LI H et al: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. I CM]. Invest. (2001) 107:1255–1262.
  • SHIH PT, BRENNAN ML, VORA DK et al.: Blocking of very late antigen-4 intergrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ. Res. (1999) 84:345–351.
  • ••This study of mice deficient in VCAMprovides compelling evidence for the role of the VCAMNLA-4 interation in the early stages of atherosclerosis.
  • KUNSCH C, MEDFORD RIVI: Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. (1999) 85(8):753–766.
  • MENG CQ: Probucol (restenosis) Daiichi. Cum: Opin. Cardiovasc. Pul Renal Invest. Drugs (2000) 2(3):294–298.
  • SOMERS PK, MEDFORD RM, SAXENA U: Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Radical Biol. Med. (2000) 28(10):1532–1537.
  • MENG CQ, ZHENG XS, HOLT LA etal.: Nitrobenzene compounds inhibit expression of VCAM- I. Bioorg. Med. Chem. Lett. (2001) 11:1823–1827.
  • PREVITALI SC, HARTUNG HP: The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. (1999) 22:30–38.
  • THEIEN BE, VANDERLUGT CL, EAGAR TN et al.: Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encepahlomyelitis. I Chit. Invest. (2001) 107:995–1006.
  • ARCHELOS JJ, PREVITALI SC, HARTUNG HP: The role of integrins in immune mediated diseases of the nervous system. TINS (1999) 22:30–38.
  • KANWAR JR, HARRISON JEB, WANG Detal.: 137 Integrins contribute to demyelinating disease of the central nervous system. Neuroimmunol (2000) 103:146–152
  • BROCKE S, PIERCY C, STEINMAN L, WEISSMAN IL, VEROMAA T: Antibodies to CD44 and integrin a4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomylitis by blocking secondary leukocyte recruitment. Proc. Nat] Acad. Li. USA (1999) 96:6896–6901.
  • REPARON-SCHUIJT CC, VAN ESCH WJE, VAN KOOTEN C et al: Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis Rheum. (2000) 43:1115–1121.
  • KITANI A, NAKASHIMA N, IZUMIHARAT etal.: Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4. j Immunol (1998) 161:4931–4938.
  • TOKUHIRA M, HOSAKA S, VOLIN MV et al.: Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum. (2000) 43:1122–1133.
  • SEIFFGE D: Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. j Rheumatol (1996) 23:2086–2091.
  • CARTER RA, WICKS IP:Vascular cell adhesion molecule 1 (CD 106): a multifaceted regulator of joint inflammation. Arthritis Rheum. (2001) 44(5):985–994.
  • BRANDTZAEG P, HARALDSEN G, HELGELAND L, NILSEN EM, RUGTVEIT J: New insights into the immunopathology of human inflammatory bowel disease. Drugs Today (1999) 35(Suppl. A):33–70.
  • HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ etal.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut homing integrin a437. Gastroenterology (1996) 111:1373–1380.
  • KATO S, HOKARI R, MATSUZAKI K et al: Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. _J. Pharmacol Esp. Ther. (2000) 295:183–189.
  • PICARELLA D, HURLBUT E ROTTMAN J, SHI X, BUTCHER E, RINGLER DJ: Monoclonal antibodies specific for 137 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAIVI-1) reduce inflammation in the colon of scid mice reconstituted with CD45RB high CD4+ T cells. I Immunol (1997) 158:2099–2106.
  • SORIANO A, SALAS A, SALAS A: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. (2000) 80:1541–1551.
  • POON BY, WARD CA, GILES WR, KUBES P: Emigrated neutrophils regulate vertricular contractillity via a4 integrin. Circ. Res. (1999) 84:1245–1251.
  • POON BY, WARD CA, COOPER CB, GILES WR, BURNS AR: a4Integrin mediates neutrophil-induced free radical injury to cardiac myocytes. j Cell Biol. (2001) 152:857–866.
  • BURNE MJ, ELGHAND OUR A, HAQ M et al.: IL-1 and TNF independent pathways mediate ICAM-1NCAM-1 up-regulation in ischemic reperfusion injury. Leukocyte Biol. (2001) 70(2):192–198.
  • RELTON JK, SLOAN KE, FREW EM, WHALLEY ET, ADAMS S), LOBB RR: Inhibition of a4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke (2001) 32:199–205.
  • PAPAYANNOPOULOU T, CRADDOCK C, NAKAMOTO B, PRIESTLEY GV, WOLF NS: The VLA-4NCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc. Natl. Acad. Sci. USA (1995) 92:9647–9651.
  • CHAN JYH, WATT SM: Adhesion receptors on haematopoietic progenitor cells. Br .j Haemtol (2001) 112:541–557.
  • WEEKES CD, KUSZYNSKI CA, SHARP JG: VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk. Lymphoma (2001) 40:631–645.
  • MICHIGAMI T, SHIMIZU N, WILLIAMS PJ etal.: Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and a431 integrin enhances production of osteoclast-stimulating activity. Blood (2000) 96:1953–1960.
  • DAMIANO JS, CRESS AE, HAZLEHURST LA, SHTIL AA, DALTON WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 93:1658–1667.
  • KWEE L, BALDWIN HS, SHEN HM, STEWART CL, BUCK CA, LAB OW MA: Defective development of the embryonic and extra embryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development (1995) 121:489–503.
  • GURTNER GC, DAVIS V, LI H, MCCOY MJ, SHARPE A, CYBULSKY MI: Targeted disruption of the murine VCAM-1 gene: essential role of VCAM-1 in chorioallontoic fusion and placentation. Genes Dev. (1995) 9:1–14.
  • KONI PA, JOSHI SK, TEMANN UA, OLSON D, BURKLY L, FLAVELL RA: Conditional vasucular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. Esp. Med. (2001) 193:741–753.
  • LEUKER CE, LABOW M, MUELLER W, WAGNER N: Neonatally induced inactivation of the vascular cell adhesion molecule-1 gene impairs B cell localization and T cell-dependent humoral immune response. j Exp. Med. (2001) 193:755–767.
  • ANTHONI D, RIJCKEN E, MENNIGEN R, SENNINGER N, BENNETT CF, SCHURMANN G: Inhibition of leukocyte-endothelial interaction by antisense oligonucleotides against VCAM-1 in a rat model of inflammatory bowel disease. Chit: Forum Esp. Kiln. Forsch. (2000:179–181.
  • ELICES M: Natalizumab Elan: Curr. Opin. Antidrillarnm. Immunomodulatory Invest. Drugs (2000) 2:228–235.
  • CARTER JL, AGIUS M, MASS M et al: A placebo-controlled, pharmacodynamic, pharmacokinetic, tolerability and safety study of three doses of intravenous Natalizumab in multiple sclerosis. Neurology (2000) 54:A259\(Suppl. 3).
  • •Reports the first reported clinical studies of the anti-a4 antibody Natalizumab in multiple sclerosis.
  • SHEREMATA WA, VOLLMER TL, STONE LA, WILLMER-HULME AJ, KOLLER M: A safety and pharmacokinetic study of intravenous Natalizumab in patients with MS. Neurology (1999) 52:1072–1074.
  • •Reports the first reported clinical studies of the anti-a4 antibody Natalizumab in multiple sclerosis.
  • TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti- a4 integrin antibody on brain lesion activity in MS. Neurology (1999) 53:466–472.
  • •Reports the first reported clinical studies of the anti-a4 antibody Natalizumab in multiple sclerosis.
  • GORDON FH, CLEMENT CWY, HAMILTON MI et al: A randomized placebo-controlled trial of a humanized monoclonal antibody to a4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268–274.
  • •Report the first clinical studies of the anti-a4 antibody in Crohn's disease.
  • GHOSH S, GOLDIN E, MALCHOW HA et al: A randomized double-blind, placebo-controlled, pan-European study of a recombinant humanized antibody to a4 integrin (AntegreMD) in moderately to severe active Crohn's disease. Gastroenterology (2001) 120:(Suppl. 1)A127–A128.
  • •Report the first clinical studies of the anti-a4 antibody in Crohn's disease.
  • GORDON FH, HAMILTON MI, FREE R et al.: Treatment of active ulcerative colitis with a recombinant humanized antibody to a-4 integrin (Antegren®). Gastroenterology (1999) 116:A726.
  • •Report the first clinical studies of the anti-a4 antibody in Crohn's disease.
  • NOWLIN DM, GORCSAN F, MOSCINSKI M, CHIANG S, LOBL TJ, CARDARELLI PM: A novel cyclic pentapeptide inhibits a4/I31 and a5/131 integrin-mediated cell adhesion. j Biol. Chem. (1993) 268:20352–20359.
  • FOTOUHI N, JOSHI E FRY D et al: The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic. Bioorg. Med. Chem. Lett. (2000) 10:1171–1173.
  • JACKSON DY, QUAN C, ARTIS DR et al.: Potent a4I31 peptide antagonists as potential anti-inflammatory agents. j Med Chem. (1997) 40:3359–3368.
  • FOTOUHI N, JOSHI P, TILLEY JW et al: Cyclic thioether peptide mimetics as VCAM-VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2000) 10:1167–1169.
  • DUTTA AS, GORMLEY JJ, COATH M et al.: Potent cyclic peptide inhibitors of VLA-4 (a431 integrin) -mediatedcell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-dArg-dArg) (ZD7349) compatible with depot formulation. j PepL Sci. (2000) 6:398–412.
  • DUTTA AS, MANDY C, GORMLEY JJ et al.: Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (a4l31 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide. I Peptide Sci. (2000) 6:321–341.
  • ARRHENIUS T, CHIEM A, ELICES M et al.: Small molecule inhibitors of the leukocyte integrin VLA-4. Peptides Chem. Struct Biol. PTOC. Am. Pept. Symp. 14th (1996)337–339.
  • ABRAHAM WM, ASHFAQ A, SIELCZAK MW, NARITA M, ARRHENIUS T, ELICES MJ: Blockade of late-phase airway response and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am. J Respir Ctit. Care Med. (1999) 156:696–703
  • RICHARD B, WAY W, HUYGHE B et al:CY-9701, a small molecule VLA-4 inhibitor modulates proinflammatory cytokines in an allergic mouse asthma model. Am. I Respit: Grit. Care Med. (1999) 159:(Suppl. 2):327.
  • CHEN LL, WHITTY A, LOBB RR, ADAMS SP, PEPINSKY RB: Multiple activation states of integrin a4131 detected through their different affinities for a small molecule ligand. I Biol. Chem. (1999) 274:13167–13175.
  • •First evidence that Kd and off rates are sensitive to the activation state of the cell expressing ce4[31.
  • CHEN LL, WHITTY A, SCOTT D et al:Evidence that ligand and metal ion binding to integrin a4l31 are regulated through a coupled equiLibrium. I Biol. Chem. (2001) 276(39)36520–36529.
  • LOCKEY P, STOPPARD A, WHITE E, WHITE M, WONG W: IVL-745, a potent, selective, low molecular weight antagonist of VLA-4 mediated cell adhesion. Am. I Respit: Grit. Care Med. (2000) 161:A201.
  • •Contains the first reports of the pharmacology of the development candidate IVL-745.
  • BAHRA P, EBS WORTH K, LAWRENCE CE, WEBBER SE, WILLIAMS RJ: The VLA-4 agtagonist IVL-745 is a novel and potent inhibitor of human lymphocyte adhesion to VCAM-1. Am. I Respir. Grit. Care Med. (2000) 161:A201.
  • •Contains the first reports of the pharmacology of the development candidate IVL-745.
  • CAIRNS JA, KAIK K, LLOYD J, WEBBER SE, WILLIAMS RJ: The VLA-4 antagonist, IVL-745 is a novel and potent inhibitor of eosinophil adhesion to VCAM. Am. I Resp. Grit. Care Med. (2000) 161:A202.
  • •Contains the first reports of the pharmacology of the development candidate IVL-745.
  • EBSWORTH K, LAWRENCE CE, WEBBER SE, WILLIAMS RJ: The VLA-4 agtagonist IVL-745 is a novel and potent inhibitor of VCAM-1 co-stimulated human T-cell activation. Am. I Respir. Grit. Care Med. (2000) 161:A201.
  • •Contains the first reports of the pharmacology of the development candidate IVL-745.
  • UNDERWOOD SL, PRINCE L, PAGE K, WEBBER SE, FOSTER ML: hi vivo profile of the novel VLA-4 antagonist IVL-745 in antigen induced airway inflammation in the rat. Am. I Respir. Grit. Care Med. (2000) 161:A199.
  • •Contains the first reports of the pharmacology of the development candidate IVL-745.
  • WATTANASIN S, WEIDMANN B, ROCHE D etal.: Design and synthesis of potent and selective inhibitors of the integrin VLA-4. Bioorg. Med. Chem. Lett. (2001) 11:2955-2958. Ica DUPLANTIER AJ, BECKIUS GE, CHAMBERS, RJ et al: Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent a431 integrin antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2593–2596.
  • MUELLER G, ALBERS M, FISCHER R etal.: Discovery and evaluation of piperidinyl carboxylic acids as potent a431 integrin antagonists. Bioorg. Med. Chem. Lett. (2001) 11:3019–3021.
  • HOLLAND GW, KASSIR JM, SCOTT IL etal.: TBC3486: novel highly potent, and selective VLA-4 antagonist. Book of Abstracts 219th American Chemical Society National Meeting, MEDI 10. March (2000). Ica KASSIR PVT, SCOTT IL, BIEDIGER RJ etal.: Novel N,N-disubstituted amides that are highly potent VLA-4 antagonists. Book of Abstracts 219th American Chemical Society National Meeting, MEDI 284. March (2000).
  • SCOTT IL, RAJU BG, REN K etal.: Novel urea derivatives that are potent VLA-4 antagonists. Book of Abstracts, 219th American Chemical Socieh National illeeting, MEDI 283. March (2000).
  • CHEN L, TILLEY JW, HAUNG TN etal.: N-Acyl phenylalanine analogues as potent small molecule VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2000) 10:725–727.
  • DE LASZLO SE, LI B, MCCAULEY E etal.: Identification of unique VLA-4 antagonists from a combinatorial library. Bioorg. Med. Chem. Lett. (2002) 12:685–688.
  • ARCHIBALD SC, HEAD JC, GOZZARD N etal.: Discovery and evaluation of potent, tyrosine-based a4I31 integrin antagonists. Bioorg. Med. Chem. Lett. (2000) 10:997–999.
  • PORTER J: From cyclic peptide to small molecule antagonists of VLA-4. 11th Symposium on medicinal chemistry in eastern England April (2000).
  • KOPKA IE, YOUNG DN, LIN LS etal.: Substituted N- (3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:637–640.
  • •The binding activity and pharmacoltinetics of all four diastereomers of a prolyl-phenylalanine derivative are reported.
  • SARANTAKIS D, BAUDY RB, BICKSLER JJ et al.: Acylated p-amino-L-phenylalanines-with VLA-4NCAM-1 inhibitory activity. Book of Abstracts, 220th American Chemical Socieo, National Meeting, MEDI 136. August (2000).
  • SARANTAKIS D, BICKSLER JJ, CANNON C et al: VLA-4NCAM inhibitors - dipeptide p-amino-L-phenylalanine amides. Book of Abstracts, 220th American Chemical Socieo, National Meeting, MEDI 137, MEDI 058. August (2000).
  • rIEEGARDEN BR, RISHTON GM, YAMAGISHI M et al: Discovery of TR-9109: a novel small molecule inhibitor of c(4131 integrin mediated cell adhesion. Book of Abstracts, 218th American Chemical Society National Meeting. August (1999).
  • SIDDURI A, TILLEY JW, HULL K et al: N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:In press.
  • CHEN L, TILLEY JW, GUTHRIE RW et al: N-Benzylpyroglutamyl-L-phenylalanine derivatives as VCAMNLA-4 antagonists. Bioorg. Med. Chem. Lett. (2000) 10:729–733.
  • SIDDURI A, TILLEY JW, CHEN L et al: N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists. Bioorg. Med Chem. Lett. (2002) 12:In press.
  • TILLEY JW, KAPLAN G, ROWAN K, SCHWINGE V, WOLITZKY B: Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists. Bioorg Med Chem. Lett. (2001) 11:1–4.
  • SIDDURI A, LOU JP, CAMPBELL R, ROWEN K, TILLEY JW: Synthesis of constrained L-phenylalanine derivatives incorporating a benzazepinone or an azepinone ring as VCAMNLA-4 antagonists. Tett. Lett. (2001) 42:8757–8760.
  • PORTER JR, ARCHIBALD SC, CHILDS, K et al.: Squaric acid derivatives as VLA-4 integrin antagonists. Bioorg. Med. Chem. Lett. (2002) 12:1051–1054.
  • CHANG LL, TROUNG, Q, MUMFORD, RA et al.: The discovery of small molecule carbamates as potent dual a4131/a4137 integrin antagonists. Bioorg. Med. Chem. Lett. (2002) 12:159–163.
  • CHEN L, TILLEY JW, TRILLES R et al: N-Acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation. Bioorg. Med. Chem. Lett. (2002) 12:137–140.
  • SIRCAR I, GUDMUNDSSON K, MARTIN R et a/.: Discovery of TR-14035; an orally active dual a4-I31 integrin antagonist. 218th American Chemical Society National Meeting. Abstracts MEDI 59 and MEDI 60. August (1999).
  • HAGMANN WK, DURETTE PL, LANZA T et al.: The discovery of sulfonated dipeptides as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2709–2713.
  • LIN LS, LANZA T, MCCAULEY E et al.: Specific and dual acting antagonists of a431 and a4I37integrins. Bioorg. Med. Chem. Lett. (2002) 12:133–136.
  • YANG GX, CHANG LL, TRUONG Q et al.: N-Tetrahydrofuroyl-W-phenylalanine derivatives as potent VLA-4 antagonists. Biaarg. Med. Chem. Lett. (2002) 12:1497–1500.
  • DOHERTY GA, YANG G, BORGES E et al.: Substituted tetrahydrofuroyl-L-phenylalanine derivatives as potent and specific VLA-4 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1501–1505.
  • LI B, DE LASZLO SE, KAMENECKA T et al.: N-(Arylacetyfi-biphenylalanines as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:In press
  • KAMENECKA TM, LANZA T, DE LASZLO SE et al: N-Aryl-prolyl-dipeptides as potent antagonists of VLA-4. Bioorg. Med. Chem. Lett. (2002) 12:In press.
  • DOHERTY GA, KAMENECKA T, MCCAULEY E et al: N-Aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:729–731
  • LIN LS, KOPKA IE, MUMFORD RA et al.: The discovery of acylated 3-amino acids as potent and orally bioavailable VLA-4 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:611–614.

Websites

  • AtheroGenics press release available at www.atherogenics.com.
  • ISIS Pharmaceuticals press release available at: www.ISIS.com
  • Biogen company press release available at: www.biogen.com
  • GlaxoSmithKline corporate web site: www.gsk.com.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.